Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTPRA | P18433 | 1/20 | 0.35 |
| ▸ | PCNA | P12004 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566905 | 0.91 | ALDH1A1 (0.43) | — | |
| SCHEMBL1385652 | 0.86 | PCNA (0.35) | PCNAITGB3ITGA2B | |
| SCHEMBL1386587 | 0.85 | SLC1A3 (0.39) | GRIA2GRIA1GRIA4GRIK5PCNA | |
| SCHEMBL2569127 | 0.85 | THRB (0.38) | PCNAITGB3ITGA2B | |
| SCHEMBL1384603 | 0.84 | ALDH1A1 (0.41) | GRIA2GRIA1GRIA4GRIK5CYP2C19 | |
| SCHEMBL1385865 | 0.84 | ITGB3 (0.45) | PCNAITGB3ITGA2B | |
| SCHEMBL1385674 | 0.83 | PPARG (0.43) | — | |
| SCHEMBL1384979 | 0.83 | PTPN1 (0.38) | PCNAITGB3ITGA2B | |
| SCHEMBL1386707 | 0.80 | ITGB3 (0.41) | PCNAITGB3ITGA2B | |
| SCHEMBL1385921 | 0.79 | MEN1 (0.35) | GRIA2GRIA1GRIA4GRIK5PCNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833072-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | claimed |
| EP-1583529-A4 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | claimed |
| EP-1583529-A2 | AMINO ACID PHENOXY ETHERS | Bexel Pharmaceuticals Inc (US) | 2005-10-12 | — | — | EP | claimed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | claimed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | claimed |
| WO-2004066964-A2 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | claimed |
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1583529-A4 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006125285-A1 | INSULIN SENSITIZATION TO SLOW DOWN PUBERTAL TEMPO AND TO AUGMENT PUBERTAL GROWTH | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1583529-A2 | AMINO ACID PHENOXY ETHERS | Bexel Pharmaceuticals Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | BEXEL PHARMACEUTICALS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004066964-A2 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142991-A1 | Amino acid phenoxy ethers | IL4I1, DNPEP, GPR119 | GRIA2 204/4885GRIA1 245/4885GRIA4 118/4885 |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | PPARA, PPARG, PPARD | GRIA2 412/4885GRIA1 364/4885GRIA4 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.